Dabrafenib (CAS: 1195765-45-7)

Short Description:

API’s Name Indication Innovator Patent Expiry Date(The U.S)
Dabrafenib  Melanoma  Novartis

(GSK R&D)

 Jul.20, 2030


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us